The Cardinal Source
CCaaS vendor recommendation.
Acme Manufacturing · For: VP IT, CFO, Board IT Subcommittee
Recommendation
Sign with NICE CXone. Begin migration October 14, 2026. Complete by March 30, 2027.
Five-year TCO: $3.94M. 18.5% savings vs. current run-rate. 21 CFR Part 11 audit-ready by go-live. MasterControl integration delivered via NICE PS team in production within 60 days of contract signing.
Sample / illustrative. This is the Decision Memo deliverable format. Buyer details are illustrative. Vendor names are real but the recommendation shown does not represent a live engagement.
Executive summary
Cardinal Source ran the Cardinal Method end-to-end across 12 weeks. We evaluated 11 CCaaS vendors and scored 6 against a Medical-Device-Manufacturing-weighted rubric (Vendor Scorecard delivered August 12). NICE CXone scored 8.15 of 10, narrowly ahead of Genesys Cloud at 8.00. The recommendation is NICE CXone. Genesys Cloud is held as a qualified alternative if commercial terms become problematic during contract negotiation.
The recommendation reflects three judgments: (1) NICE CXone's 21 CFR Part 11 implementation is one validation cycle ahead of Genesys, which materially lowers FDA inspection risk in the first 12 months post-go-live; (2) NICE's MasterControl integration depth is sufficient to satisfy the 4-minute call-to-record SLA without third-party integration risk; (3) the five-year TCO premium of ~$48K/year versus Genesys is justified by the regulatory risk reduction.
Why NICE CXone — three reasons
1 · 21 CFR Part 11 — proven at peer manufacturers
NICE CXone has three medical-device-manufacturer deployments where the Part 11 validation package was reviewed during FDA pre-inspection without findings. Genesys Cloud has one. The remaining vendors have zero. This is the single highest-weight dimension in our rubric (25%) and the dimension most directly tied to material Acme regulatory exposure.
2 · MasterControl integration — production-grade, not partner-built
NICE's MasterControl integration runs in production at two peer manufacturers we reference-checked. Both confirmed sub-3-minute call-to-record latency at full load, well inside Acme's 4-minute SLA target. Five9 and Talkdesk rely on partner-built integrations, which adds 6 weeks of implementation risk and a dependency on a third-party integrator we don't control.
3 · AI / voice analytics roadmap — the only production-ready offering
NICE's Enlighten AI suite is in production at peer manufacturers today. Most competitors have announced equivalent capabilities; only NICE has shipped. While Acme's primary use case doesn't require AI/voice analytics in year 1, the analytics roadmap will materially affect quality-system efficiency in years 2–3.
Commercial terms — negotiated
| Component | Quoted | Negotiated | 5-yr value |
|---|---|---|---|
| Licensing (360 seats) | $118/seat/mo | $96/seat/mo | $2,073,600 |
| Professional services (one-time) | $640,000 | $420,000 | $420,000 |
| MasterControl integration (one-time) | $185,000 | $140,000 | $140,000 |
| Part 11 validation package | $95,000 | Included | $0 |
| Training (one-time) | $72,000 | $48,000 | $48,000 |
| Support (Premier tier) | $144,000/yr | $120,000/yr | $600,000 |
| Concurrent agent overage buffer (40 seats) | $118/seat/mo | 0 for 6 mo, then $84/seat/mo | $201,600 |
| 5-year total | $3,483,200 | ||
| Run-rate at year 3 | $668,160/yr |
Implementation plan
| Phase | Window | Sites | Risk profile |
|---|---|---|---|
| Validation + UAT | Oct 14 – Nov 30, 2026 | 2 pilot sites (Indianapolis, Phoenix HQ) | Medium |
| Phase 1 — manufacturing sites | Dec 1 – Jan 31, 2027 | 24 sites | Low |
| Phase 2 — clinical affairs | Feb 1 – Feb 28, 2027 | 18 sites (highest FDA risk) | High |
| Phase 3 — remaining | Mar 1 – Mar 30, 2027 | 34 sites | Low |
| Parallel run + rollback period | Through Jun 30, 2027 | All sites | Low (UCCE retained) |
Risk register
| Risk | Likelihood | Impact | Mitigation |
|---|---|---|---|
| Part 11 validation finds gap during FDA pre-inspection | Medium | High | NICE includes Part 11 audit package + on-site validation; QA pre-review before Phase 2 launch |
| MasterControl integration fails the 4-min SLA | Low | Medium | 30-day burn-in with daily SLA reporting; rollback triggered if SLA misses 2 consecutive days |
| NICE PS team booked elsewhere, delays start | Low | Medium | Contract includes PS team commitment date + $50K/week delay penalty |
| UCCE end-of-support before migration complete | Low | High | Cisco extended-support agreement secured through June 2027 as fallback ($28K) |
| Acme staff capacity for parallel-run period | Medium | Low | NICE PS provides supplementary L1 support during weeks 1–6 of each phase |
Decision request
We request approval to execute the NICE CXone contract as negotiated. Contract draft is available for legal review. Suggested decision path:
- This week: Legal review of negotiated contract (Cardinal Source available to walk through provisions)
- By September 17: Board IT Subcommittee approval
- By September 24: Contract execution
- October 14: Implementation kickoff per plan above
Alternative
If contract negotiation with NICE cannot deliver the negotiated terms shown above, or if PS team capacity creates an unacceptable delay, Genesys Cloud remains a qualified alternative. Cardinal Source can re-engage Genesys within 5 business days. Decision authority retained by VP, Information Technology.